Table 3 Accelerometry-based physical activity by type of disease, sex, and age categories
Type of disease | Sex | Age categories | |||||
|---|---|---|---|---|---|---|---|
UC (n = 20) | CD (n = 41) | Male (n = 27) | Female (n = 35) | 10–13 y (n = 13) | 14–17 y (n = 25) | 18–20 y (n = 24) | |
minutes (95% CI) | minutes (95% CI) | minutes (95% CI) | minutes (95% CI) | minute (95% CI) | minutes (95% CI) | minutes (95% CI) | |
ENMO (mg) | 32.0 (28.9–35.1) | 31.3 (27.9–34.7) | 36.2 (31.9–40.5) | 27.8 (25.6–30.0) | 37.2 (28.6–45.7) | 31.4 (28.5–34.3) | 28.5 (25.2–31.7) |
Unbouted MVPA (135 mg) | 81.1 (68.4–93.8) | 76.6 (65.8–87.3) | 95.4 (82.2–108.5) | 64.3 (56.2–72.4) | 92.9 (65.7–120.1) | 79.4 (67.7–91.1) | 68.2 (57.9–78.5) |
Unbouted MVPA (210 mg) | 33.9 (26.9–40.9) | 30.7 (23.5–37.9) | 42.6 (33.4–51.8) | 23.1 (18.6–27.6) | 47.2 (29.4–64.9) | 30.5 (23.4–37.8) | 24.3 (19.1–29.5) |
Bouted MVPA (135 mg) | 14.9 (10.5–19.4) | 17.1 (12.5–21.8) | 21.4 (15.2–34.9) | 12.5 (9.1–15.9) | 23.2 (12.3–34.0) | 18.3 (13.6–22.9) | 10.6 (6.3–15.0) |
Bouted MVPA (210 mg) | 4.2 (2.0–6.4) | 3.1 (1.4–4.8) | 4.5 (2.2–6.9) | 2.6 (1.1–4.1) | 6.4 (1.8–11.1) | 3.7 (1.9–5.5) | 1.5 (0.2–2.9) |